← Every company
Incyte Corp Patents
What Incyte Corp has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
INCY on carbonthat →Filings on file
58
Granted
0
Still pending
58
Filed under
3 names
58 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORSA61K 31/4155, A61K 31/519, A61P 17/10, A61P 37/00, A61P 37/02, A61P 17/00, A61P 29/00, A61K 9/0014, A61K 9/0053, A61K 31/437, A61K 31/573, A61K 45/06, A61K2300/00Filed as Incyte Corporation2026-05-11Michael D. Howell | pending |
| TREATMENT OF HIDRADENITIS SUPPURATIVA USING JAK INHIBITORSA61K 31/4155, A61K 31/519, A61P 17/10, A61P 37/00, A61P 37/02, A61P 17/00, A61P 29/00, A61K 9/0014, A61K 9/0053, A61K 31/437, A61K 31/573, A61K 45/06, A61K2300/00Filed as Incyte Corporation2026-03-30Michael D. Howell | pending |
| PROCESSES FOR PREPARING TRICYCLIC AMINESC07D 487/04, C07D 231/04Filed as Incyte Corporation2026-03-19Jianguo Wu | pending |
| PROCESSES FOR PREPARING TRICYCLIC AMINESFiled as INCYTE CORPORATION2026-03-19JIACHENG ZHOU | pending |
| JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF VITILIGOA61K 31/415, A61K 31/4155, A61P 17/00, A61K 31/437, A61K 31/519, A61K 45/06Filed as Incyte Corporation2026-03-17Paul Smith | pending |
| POVORCITINIB FOR TREATMENT OF HIDRADENITIS SUPPURATIVAA61K 31/4155, A61P 17/10, A61P 17/00, A61K 9/0019, A61K 9/2018, A61K 9/2027, A61K 9/2054Filed as Incyte Corporation2026-03-13Kurt Andrew Brown | pending |
| USE OF POVORCITINIB FOR TREATMENT OF HIDRADENITIS SUPPURATIVAFiled as INCYTE CORPORATION2026-03-13KURT ANDREW BROWN | pending |
| PYRAZOLE-FUSED COMPOUNDS AS VRK1 INHIBITORSC07D 471/04, A61P 35/00, A61K 31/437, A61K 31/439, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/4725, A61K 31/4985, A61K 31/499, A61K 31/519, A61K 31/5377, A61K 31/538, C07B 59/002, C07D 487/04, C07D 487/10, C07D 519/00Filed as Incyte Corporation2026-03-13Huan Chen | pending |
| FUSED BICYCLIC COMPOUNDS AS VRK1 INHIBITORSC07D 471/04, A61P 35/00, A61K 31/437, A61K 31/439, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/4725, A61K 31/4985, A61K 31/499, A61K 31/519, A61K 31/5377, A61K 31/538, C07B 59/002, C07D 487/04, C07D 487/10, C07D 519/00Filed as Incyte Corporation2026-03-13Le Zhao | pending |
| FUSED BICYCLIC COMPOUNDS AS VRK1 INHIBITORSFiled as INCYTE CORPORATION2026-03-13DIPENDU DAS | pending |
| PYRAZOLE-FUSED COMPOUNDS AS VRK1 INHIBITORSC07D 471/04, A61P 35/00, A61K 31/437, A61K 31/439, A61K 31/444, A61K 31/4545, A61K 31/4709, A61K 31/4725, A61K 31/4985, A61K 31/499, A61K 31/519, A61K 31/5377, A61K 31/538, C07B 59/002, C07D 487/04, C07D 487/10, C07D 519/00Filed as Incyte Corporation2026-03-13Yong Li | pending |
| COMBINATION TREATMENTS COMPRISING ANTICANCER AGENTS AND AN ANTI-TGFBR2/PD-1 BISPECIFIC ANTIBODYFiled as INCYTE CORPORATION2026-03-13THOMAS KARASIC | pending |
| COMBINATION TREATMENTS COMPRISING ANTICANCER AGENTS AND AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODYA61K 39/3955, C07K 16/22, A61P 35/00, A61K 31/282, A61K 31/4745, A61K 31/513, A61K 31/519, A61K 39/39558, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545, C07K 16/2818, C07K 16/2863, C07K2317/31, A61K2300/00Filed as Incyte Corporation2026-03-13Thomas Karasic | pending |
| PYRAZOLE-FUSED COMPOUNDS AS VRK1 INHIBITORSFiled as INCYTE CORPORATION2026-03-13YONG LI | pending |
| RUXOLITINIB FORMULATION FOR REDUCTION OF ITCH IN ATOPIC DERMATITISA61K 9/06, A61K 31/519, A61P 17/00, A61K 9/0014, A61K 9/107, A61K 47/14Filed as Incyte Corporation2026-03-05Michael Kuligowski | pending |
| SOLID FORMS OF A KINASE INHIBITORFiled as INCYTE CORPORATION2026-02-23JIANXIN FENG | pending |
| COMBINATION TREATMENTS COMPRISING ANTICANCER AGENTS AND AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODYFiled as Incyte Corporation2026-01-27Thomas Karasic | pending |
| FURANYL OR THIENYL PYRIMIDINES AS CDK4 INHIBITORSC07D 495/04, A61P 35/00, A61K 31/136, A61K 31/381, A61K 31/40, A61K 31/436, A61K 31/437, A61K 31/4439, A61K 31/4741, A61K 31/4745, A61K 31/506, A61K 31/519, A61K 31/5377, A61K 31/565, C07D 491/048Filed as Incyte Corporation2026-01-23Ming Xiang | pending |
| FURANYL OR THIENYL PYRIMIDINES AS CDK4 INHIBITORSFiled as INCYTE CORPORATION2026-01-23MING XIANG | pending |
| COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITORA61P 37/06, A61K 31/519, A61K 31/517, A61K 45/06, A61K2300/00Filed as Incyte Corporation2026-01-21Michael Peel | pending |
| TOPICAL FORMULATIONS OF RUXOLITINIB WITH AN ORGANIC AMINE PH ADJUSTING AGENT FOR TREATMENT OF SKIN DISEASESA61K 31/519, A61K 9/0014, A61K 9/06, A61K 9/10, A61K 9/12, A61K 9/124, A61K 31/4985, A61K 47/06, A61K 47/10, A61K 47/18, A61K 47/183, A61K 47/186, A61K 47/26Filed as INCYTE CORPORATION2026-01-07Naresh MODEPALLI | pending |
| ANTIBODIES THAT BIND TO COLONY STIMULATING FACTOR 1 RECEPTOR (CSF-1R) AND USES THEREOFFiled as INCYTE CORPORATION2025-12-29CORY M. SUTHERLAND | pending |
| Antibodies that Bind to Colony Stimulating Factor 1 Receptor (CSF-1R) and Uses ThereofA61P 37/06, C07K 16/2866, A61K2039/505, C07K2317/565, C07K2317/76, C07K2317/92Filed as Incyte Corporation2025-12-29Cory M. Sutherland | pending |
| SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORSC07D 471/14, A61P 7/00, A61P 1/16, A61P 19/02, A61P 11/00, A61P 35/00, A61K 31/519, A61K 31/5377, C07D 471/04, C07D 471/20, C07D 471/22, C07D 491/22, C07D 495/14, C07D 498/14, C07D 498/22Filed as Incyte Holdings Corporation2025-12-22Liangxing Wu | pending |
| TREATMENT OF CLONAL HEMATOPOIETIC DISORDERS USING KINASE INHIBITORSFiled as INCYTE CORPORATION2025-12-19RICARDO MACARRÓN LARUMBE | pending |
| TREATMENT OF CLONAL HEMATOPOIETIC DISORDERS USING KINASE INHIBITORSA61K 31/437, A61K 31/4375, A61P 7/02, A61P 43/00, A61P 9/00, A61P 35/00, A61K 31/4985, C07K 16/18Filed as Incyte Corporation2025-12-19Ricardo Macarrón Larumbe | pending |
| PYRAZOLE-FUSED COMPOUNDS AS VRK1 INHIBITORSFiled as Incyte Corporation2025-12-11Yong Li | pending |
| FUSED BICYCLIC COMPOUNDS AS VRK1 INHIBITORSFiled as Incyte Corporation2025-12-11Le Zhao | pending |
| PYRAZOLE-FUSED COMPOUNDS AS VRK1 INHIBITORSFiled as Incyte Corporation2025-12-11Huan Chen | pending |
| Heteroarylsulfonyl Compounds As USP18 InhibitorsC07D 487/10, A61K 31/4025, A61K 31/4035, A61K 31/404, A61K 31/4353, A61K 31/454, A61K 31/4709, A61K 31/4725, A61K 31/496, A61K 31/4995, A61K 31/551, C07D 401/12, C07D 401/14, C07D 403/12, C07D 403/14, C07D 405/14, C07D 409/14, C07D 471/04, C07D 487/08Filed as Incyte Corporation2025-12-02Joseph Barbosa | pending |
| HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORSC07D 413/12, A61P 31/00, A61P 37/04, A61P 31/12, A61P 35/00, C07D 213/81, C07D 213/84, C07D 237/24, C07D 239/28, C07D 241/24, C07D 401/06, C07D 401/12, C07D 401/14, C07D 405/12, C07D 405/14Filed as Incyte Corporation2025-11-25Liangxing Wu | pending |
| PHARMACEUTICAL COMBINATIONS FOR TREATING TUMOR COMPRISING ANTI-CD19 ANTIBODY AND NATURAL KILLER CELLA61P 35/00, A61K 39/3955, A61P 35/02, A61K2239/48, A61K2239/46, A61K2239/31, A61K2239/38, A61K 40/42, A61K 40/15, A61K 35/17, A61K2039/505, A61K2039/515, A61K2039/54, A61K2039/545, A61K2300/00, C07K 16/2803, C07K 16/2887, C07K 16/2896, C07K2317/565, C07K2317/732, C12N 5/0636, C12N 5/0646, C12N2501/20, C12N2501/515, C12N2502/11Filed as Incyte Corporation2025-11-14Jung Hyun Her | pending |
| KRAS INHIBITORSA61K 31/4745, C07D 471/04, A61P 35/00, A61K 31/497, A61K 31/4995, A61K 31/501, C07B 59/002, C07D 471/06, C07D 519/00Filed as Incyte Corporation2025-11-12Alexander Sokolsky | pending |
| KRAS INHIBITORSFiled as INCYTE CORPORATION2025-11-12ALEXANDER SOKOLSKY | pending |
| 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORSA61K 31/5365, C07D 401/14, A61P 35/00, A61K 31/517, A61K 31/519, A61K 31/5377, C07D 405/14, C07D 417/14, C07D 471/04, C07D 487/04, C07D 498/04Filed as Incyte Corporation2025-11-06Liana Hie | pending |
| PYRIMIDINE INDOLES AS CDK4 INHIBITORSC07D 401/14, C07D 491/107, A61P 35/00, A61K 31/506, A61K 45/06, C07B 59/002, C07B2200/05, C07D 405/14, C07D 487/10Filed as Incyte Corporation2025-11-04Peter Niels Carlsen | pending |
| PYRIMIDINE INDOLES AS CDK4 INHIBITORSFiled as INCYTE CORPORATION2025-11-04PETER NIELS CARLSEN | pending |
| SALTS OF AN FGFR INHIBITORA61P 35/00, C07D 471/14, A61K 31/5377, C07B2200/13, C07C 57/15, C07C 59/255, C07C 65/10, C07C 309/65, C07C 309/73Filed as Incyte Corporation2025-10-23Zhongjiang Jia | pending |
| COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND CHEMOTHERAPY COMBINATIONSFiled as INCYTE CORPORATION2025-10-22MATTHEW FARREN | pending |
| PROCESSES FOR PREPARING KRAS INHIBITORSFiled as INCYTE CORPORATION2025-10-22WENXING GUO | pending |
| COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITORFiled as INCYTE CORPORATION2025-10-22MATTHEW FARREN | pending |
| COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND CHEMOTHERAPY COMBINATIONSA61K 31/4745, A61P 35/04, A61P 35/00, A61K 31/513, A61K 31/519, A61K 31/555Filed as Incyte Corporation2025-10-22Matthew Farren | pending |
| PROCESSES FOR PREPARING KRAS INHIBITORSC07D 471/04, A61P 35/00, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 31/4745, C07D 401/14Filed as Incyte Corporation2025-10-22Wenxing GUO | pending |
| COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITORA61K 31/4745, A61K 47/643, A61P 35/00, A61K 31/337, A61K 31/4748, A61K 31/7068, A61K 45/06, A61K2300/00Filed as Incyte Corporation2025-10-22Matthew Farren | pending |
| PROCESS AND INTERMEDIATES FOR PREPARING A JAK INHIBITORC07D 487/04, A61K 31/519, C07B2200/13, C07C 59/255, C07C 255/31, C07D 239/28Filed as Incyte Corporation2025-10-21Jiacheng Zhou | pending |
| COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITORFiled as Incyte Corporation2025-10-20Matthew Farren | pending |
| COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND CHEMOTHERAPY COMBINATIONSFiled as Incyte Corporation2025-10-17Matthew Farren | pending |
| BICYCLIC AMINES AS CDK2 INHIBITORSA61K 31/4545, C07D 471/04, A61P 35/00, A61K 31/4985, C07D 487/04, C07D 519/00, G01N 33/6893, G01N2440/14, G01N2800/52Filed as Incyte Corporation2025-10-02Yingda Ye | pending |
| TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1A61P 31/00, C07D 495/14, A61P 37/00, A61P 35/00, A61K 31/437, A61K 31/444, A61K 31/496, A61K 31/497, A61K 31/501, A61K 31/506, A61K 31/5377, C07D 519/00Filed as Incyte Corporation2025-10-02Stacey Shepard | pending |
| CRYSTALLINE SOLID FORMS OF A BET INHIBITORA61K 31/536, A61K 31/538, C07D 471/04, A61P 31/22, A61P 7/00, A61P 17/06, A61P 21/00, A61P 21/04, A61P 37/02, A61P 25/28, A61P 31/00, A61P 43/00, A61P 1/16, A61P 11/06, A61P 31/12, A61P 31/20, A61P 37/06, A61P 17/00, A61P 19/02, A61P 31/14, A61P 31/18, A61P 35/02, A61P 37/08, A61P 3/10, A61P 31/04, A61P 1/00, A61P 11/00, A61P 25/00, A61P 29/00, A61P 11/02, A61P 35/00, A01M 31/06, A61K 31/437, C07B2200/13, C07D 471/02, C07F 5/025Filed as Incyte Corporation2025-09-23Shili Chen | pending |
| COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMSA61K 31/519, A61K 31/538, A61P 35/00Filed as Incyte Corporation2025-09-19Matthew Stubbs | pending |
| TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITORA61K 31/519, A61P 17/00, A61K 9/0014, A61K 9/06, A61K 9/107Filed as Incyte Corporation2025-09-18Kathleen BUTLER | pending |
| USE OF POVORCITINIB FOR TREATMENT OF HIDRADENITIS SUPPURATIVAFiled as Incyte Corporation2025-09-12Kurt Andrew Brown | pending |
| KRAS INHIBITORSFiled as INCYTE CORPORATION2025-09-11ALEXANDER SOKOLSKY | pending |
| SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORSA61K 31/5377, C07D 487/04, A61P 35/00, A61K 31/53, C07D 401/14, C07D 403/14, C07D 471/04, C07D 487/02, C07D 495/04, C07D 498/04, C07D 519/00Filed as Incyte Corporation2025-09-11Yang Li | pending |
| SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORSA61K 31/519, C07D 487/04, C07D 471/04, C07D 519/00Filed as Incyte Corporation2025-09-11Shicheng Shi | pending |
| KRAS INHIBITORSA61K 31/551, C07D 409/14, A61P 35/00, A61K 31/506, C07D 471/04, C07D 487/04, C07D 487/08, C07D 487/10, C07D 491/08, C07D 495/04, C07D 498/04, C07D 498/06, C07D 498/10, C07D 513/04, C07D 519/00Filed as Incyte Corporation2025-09-11Alexander Sokolsky | pending |
| METHODS AND COMPOSITIONS FOR RADIOPROTECTION AND MITGATION OF RADIATION-INDUCED INJURY USING KINASE INHIBITORSFiled as INCYTE CORPORATION2025-09-03ALBERT ASSAD | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on INCY
Company overviewEverything on INCY in one place, with the price.SEC filingsWhat INCY's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat INCY's own officers and directors buy and sell.Planned salesSales INCY insiders have filed notice of.Who owns itEvery manager reporting a position in INCY.Funds holding itWhich funds and ETFs hold INCY, and how big a bet.LobbyingWhat INCY spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on INCY's account, and who they worked for.Federal contractsWhat federal agencies pay INCY.